Feb 7th 2023 - Mar 21st 2023
It can be shown that treatment bringing back indep... See more
$AVXL This may show why Anavex is definitely on th... See more
Feb 7th 2023 - Mar 21st 2023
The introduction of Briumvi reduces the infusion t... See more
In pooled post hoc analyses of ULTIMATE I and II, ... See more
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.Feb 7th 2023 - Mar 21st 2023
$XERS On Gvoke, "better than expected growth&... See more
QoQ growth would still increase by ~40% with no new patients.
It can be shown that treatment bringing back independence is less costly than the nursing homes and medical staff.
$AVXL This may show why Anavex is definitely on the right path by using patients personal genetics to determine dosage.
Pill = best possible treatment course.
Many claim him to be selfish and unconcerned with others, I see a different Missling, with humility and a deep concern for patients who are suffering.
Half the patients improved over baseline over 1 year.
Blarcamesine’s Phase III clinical trials show similar levels of significant improvement in communication and interaction, as patients had statistically significant improvement in the RSBQ primary endpoint of 72.2% compared to 38.5% on placebo. .
And better still for just those 85% carrying the normal SigmaR1 gene as well as for APOE2 and 3 patients.
new clinical trial results show great promise for treating early Alzheimer’s, giving renewed hope for effective treatments.
Anavex has over 760 patients that have taken it without any significant issues. .
The introduction of Briumvi reduces the infusion time to one hour, shortening the patients’ time spent in a clinical setting and allowing them to enhance their quality of life.”
In pooled post hoc analyses of ULTIMATE I and II, ublituximab was associated with significant treatment benefit across multiple efficacy measures at Week 96 versus teriflunomide in participants who had not received prior DMT.
ATNM just published very good data from their P3 trail which is great news for Acute myeloid leukemia patients.
Remember that we are ultimately at the beginning of commercialization and quite possible the safest spot to be with the current facts on our superior Briumvi treatment and best pricing for market share penetration.
beyond TG doing well, and us all making a ton of profit, i genuinely hope that this is the answer a lot of MS patients need to help them navigate & improve their illness.
Getting the best available treatment for the lowest price is a no brainer.
We have built what we consider to be a best-in-class team to support this launch, as well as a robust patient support program designed to aid in accessing BRIUMVI at all points through the treatment journey.
They're FDA approved, have the best in class treatment, and is more affordable than the others.
Major upgrade for patients and infusion centers -No major health threats like breast cancer or sever liver damage like main competition
$TGTX possibly the best therapy available for MS patients that exists today!
$XERS On Gvoke, "better than expected growth": "Opportunity remains huge, and you don't have to find patients.
QoQ growth would still increase by ~40% with no new patients.
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
Newest product Recorlev just rolled out Q1, huge potential, new best in class treatment for advanced Cushings.
